{"transactions":[{"id":1098069,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":77874,"kind":"person","name":"Liu David R.","position":1,"cik":"0001664439","reported_name":"Liu David R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-01T20:03:52.000Z","date":"2025-06-30","kind":"purchase","planned":true,"acquired":true,"shares":21000,"price":2.5157,"value":52829.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.44 to $2.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":20240945,"source":{"system":"sec-edgar","filing":"0001628280-25-033754","document":"wk-form4_1751400224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025033754/wk-form4_1751400224.xml","form_type":"4"}},{"id":1103994,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":77874,"kind":"person","name":"Liu David R.","position":1,"cik":"0001664439","reported_name":"Liu David R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-23T20:33:56.000Z","date":"2025-06-23","kind":"purchase","planned":true,"acquired":true,"shares":21000,"price":2.162,"value":45402.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.06 to $2.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":20219945,"source":{"system":"sec-edgar","filing":"0001628280-25-032626","document":"wk-form4_1750710792.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025032626/wk-form4_1750710792.xml","form_type":"4"}},{"id":1109994,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":77874,"kind":"person","name":"Liu David R.","position":1,"cik":"0001664439","reported_name":"Liu David R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-16T21:14:52.000Z","date":"2025-06-16","kind":"purchase","planned":true,"acquired":true,"shares":21000,"price":1.4855,"value":31195.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.46 to $1.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":20198945,"source":{"system":"sec-edgar","filing":"0001628280-25-031637","document":"wk-form4_1750108485.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025031637/wk-form4_1750108485.xml","form_type":"4"}},{"id":1113725,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":77874,"kind":"person","name":"Liu David R.","position":1,"cik":"0001664439","reported_name":"Liu David R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-12T20:49:34.000Z","date":"2025-06-11","kind":"purchase","planned":true,"acquired":true,"shares":21000,"price":1.5995,"value":33589.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.53 to $1.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":20177945,"source":{"system":"sec-edgar","filing":"0001628280-25-031045","document":"wk-form4_1749761367.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025031045/wk-form4_1749761367.xml","form_type":"4"}},{"id":1822914,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":77874,"kind":"person","name":"Liu David R.","position":1,"cik":"0001664439","reported_name":"Liu David R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-26T12:29:32.000Z","date":"2023-07-21","kind":"gift","planned":false,"acquired":false,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 Amendment is being filed solely to report the disposition as a bona fide gift by the Reporting Person of the Issuer's common stock to a 501(c)(3) charitable organization for no consideration."}],"balance_after":20156945,"source":{"system":"sec-edgar","filing":"0001894562-23-000032","document":"wf-form4a_169037455528840.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456223000032/wf-form4a_169037455528840.xml","form_type":"4/A","original_submission_date":"2023-07-25"}},{"id":1823623,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":77874,"kind":"person","name":"Liu David R.","position":1,"cik":"0001664439","reported_name":"Liu David R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-26T00:15:11.000Z","date":"2023-07-21","kind":"gift","planned":false,"acquired":false,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20156945,"source":{"system":"sec-edgar","filing":"0001894562-23-000030","document":"wf-form4_169033049649105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000189456223000030/wf-form4_169033049649105.xml","form_type":"4"}},{"id":2131725,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":77874,"kind":"person","name":"Liu David R.","position":1,"cik":"0001664439","reported_name":"Liu David R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-10-27T00:00:53.000Z","date":"2022-10-24","kind":"exercise","acquired":false,"shares":1000001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Series A Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Series A Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Series A Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":321665},"source":{"system":"sec-edgar","filing":"0001628280-22-027123","document":"wf-form4_166682883819559.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828022027123/wf-form4_166682883819559.xml","form_type":"4"}},{"id":2131724,"issuer":{"id":5281,"kind":"organization","name":"Prime Medicine, Inc."},"owners":[{"id":77874,"kind":"person","name":"Liu David R.","position":1,"cik":"0001664439","reported_name":"Liu David R.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T00:00:53.000Z","date":"2022-10-24","kind":"exercise","acquired":true,"shares":321665,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Series A Preferred Stock had no expiration date."}],"balance_after":21156945,"source":{"system":"sec-edgar","filing":"0001628280-22-027123","document":"wf-form4_166682883819559.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828022027123/wf-form4_166682883819559.xml","form_type":"4"}}]}